Assertio Holdings (ASRT)于2024年11月8日讨论了其第三季度业绩,由首席执行官Brendan O'Grady和首席财务官Ajay Patel主持电话会议。公司报告本季度总产品销售额略有下降,为2870万美元,低于上一季度的3070万美元,主要是由于INDOCIN销售额下降。尽管整体销售有所下滑,但Assertio的旗舰产品ROLVEDON仍保持了1500万美元的稳定销售。

Third Quarter Total Net Product Sales of $28.7 MillionRolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 ...

Q3 2024 Earnings Call Transcript November 11, 2024 Operator: Thank you for standing by. My name is John, and I’ll be your conference operator today. At this time, I would like to welcome everyone to ...

Reports Q3 revenue $$29.2M , consensus $28.87M.”Third quarter results reflected solid performance as we continue to establish Rolvedon as ...

Thank you for standing by. My name is John, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Assertio Holdings third-quarter results conference call.

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) ...

Get detailed information on Indomethacin, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

You may be keeping tabs on your salt intake and clocking your steps, but did you know that certain everyday medications could be sneaking up on your blood %% ...

We believe the timeline for the Spectrum acquisition was rushed because Assertio’s leadership was aware that its own flagship product, Indocin, was at imminent risk of losing exclusivity and facing ...

Many types of medications, including over-the-counter (OTC) and prescription drugs, can help relieve joint pain due to ...

纽约 - 总部位于纽约市的投资咨询公司The Buxton Helmsley Group, Inc. (BHG)因Assertio Holdings, Inc. (NASDAQ:ASRT)在其产品Rolvedon和收购Spectrum Pharmaceuticals过程中涉嫌欺诈而将其投资头寸转为做空。BHG声称，Assertio董事会一直忽视与产品相关的欺诈和不当行为的证据，这导致在收购Spec ...